All In Biotech

Drug Trial Radar · NCT07536282

Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

A Phase I/IIa, Randomized, Double Blind, Placebo Controlled, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of NWRD09 Injection in Female Participants With Persistent HPV16 Infection

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Sep 2027

Study completion Nov 2027

Sponsor

Sponsor type
Industry
First posted
Apr 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with persistent HPV16 infection, and to determine the MTD, and/or RP2D of NWRD09.

Conditions

  • Persistent HPV16 Infection

Interventions

  • NWRD09Biological

    Participants will receive 4 injections of NWRD09 via IM to the lateral deltoid region of the upper arm, at D1 (W0D1), D15 (W2D1), D29 (W4D1) and D85 (W12D1)

  • PlaceboBiological

    Participants will receive 4 injections of Placebo via IM to the lateral deltoid region of the upper arm, at D1 (W0D1), D15 (W2D1), D29 (W4D1) and D85 (W12D1)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of local and systemic adverse events (AEs).Time frame: Up to Week 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Medical Center

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.